{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:42Z","timestamp":1791335622162,"version":"4.3.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jtho.2017.05.024","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T07:46:58Z","timestamp":1497685618000},"page":"1421-1433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural\u00a0Mesothelioma"],"prefix":"10.1016","volume":"12","author":[{"given":"Steven C.","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Yee","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela B.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Madore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trina","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir H.","family":"Sarun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"van Zandwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2017.05.024_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson BW MA","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.024_bib3","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br\u00a0J Cancer"},{"key":"10.1016\/j.jtho.2017.05.024_bib4","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a\u00a0randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.024_bib6","first-page":"492608","article-title":"Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis","volume":"2012","author":"Matsuzaki","year":"2012","journal-title":"J\u00a0Biomed Biotechnol"},{"key":"10.1016\/j.jtho.2017.05.024_bib7","first-page":"516","article-title":"Inflammation in malignant mesothelioma\u2014friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2017.05.024_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/14737140.2016.1162100","article-title":"A\u00a0catalogue of treatment and technologies for malignant pleural mesothelioma","volume":"16","author":"Schunselaar","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jtho.2017.05.024_bib9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2017.05.024_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtho.2017.05.024_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/107327481402100112","article-title":"Special report\u2014update on immune checkpoint inhibitors in lung cancer","volume":"21","author":"Creelan","year":"2014","journal-title":"Cancer Control"},{"key":"10.1016\/j.jtho.2017.05.024_bib12","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma","volume":"127","author":"Gee","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2017.05.024_bib13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.024_bib14","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.024_bib15","series-title":"Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18\u201322; Philadelphia, PA","first-page":"CT103","article-title":"Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028 [abstract]","author":"Alley","year":"2015"},{"key":"10.1016\/j.jtho.2017.05.024_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2017.05.024_bib17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/07357900801941852","article-title":"TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells","volume":"26","author":"Qian","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jtho.2017.05.024_bib18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jtho.2017.05.024_bib19","doi-asserted-by":"crossref","first-page":"e0123410","DOI":"10.1371\/journal.pone.0123410","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on\u00a0activation of NF-kappaB","volume":"10","author":"Gowrishankar","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2017.05.024_bib20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to\u00a0BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.024_bib21","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1158\/0008-5472.CAN-14-0847","article-title":"STAT1 drives tumor progression in serous papillary endometrial cancer","volume":"74","author":"Kharma","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.024_bib22","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.024_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2015.05.030","article-title":"EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB","volume":"463","author":"Lin","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtho.2017.05.024_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1476-4598-8-91","article-title":"Mechanisms of FUS1\/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects","volume":"8","author":"Ivanova","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2017.05.024_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cancergencyto.2003.10.006","article-title":"Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment","volume":"152","author":"Kettunen","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.jtho.2017.05.024_bib26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/humu.22014","article-title":"A\u00a0frequent somatic mutation in CD274 3\u2032-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding","volume":"33","author":"Wang","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jtho.2017.05.024_bib27","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Comm"},{"key":"10.1016\/j.jtho.2017.05.024_bib28","first-page":"108","article-title":"PDL1 Regulation by p53 via miR-34","author":"Cortez","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2017.05.024_bib29","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2017.05.024_bib30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/bjc.2013.731","article-title":"An RNAi-based screen reveals PKL1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma","volume":"110","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2017.05.024_bib32","series-title":"World Health Organisation Classification of Tumours of the Lung, Pleura, Thymus and Heart","year":"2004"},{"key":"10.1016\/j.jtho.2017.05.024_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/PAT.0b013e328342016c","article-title":"Validation of tissue microarray technology in malignant pleural mesotheloma","volume":"43","author":"Kao","year":"2011","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2017.05.024_bib34","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molonc.2014.11.007","article-title":"MiR-Score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma","volume":"9","author":"Kirschner","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib36","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib37","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.024_bib38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-13-0065","article-title":"Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair","volume":"12","author":"Kryeziu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2017.05.024_bib39","first-page":"321","article-title":"Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase","volume":"5","author":"Reid","year":"2009","journal-title":"J\u00a0RNAi Gene Silencing"},{"key":"10.1016\/j.jtho.2017.05.024_bib40","doi-asserted-by":"crossref","first-page":"23480","DOI":"10.18632\/oncotarget.4346","article-title":"miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma","volume":"6","author":"Williams","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2017.05.024_bib41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.jtho.2017.05.024_bib42","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/1541-7786.MCR-14-0442","article-title":"Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma","volume":"13","author":"Birnie","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.024_bib43","doi-asserted-by":"crossref","first-page":"27480","DOI":"10.1074\/jbc.M113.491803","article-title":"Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells","volume":"288","author":"Fan","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2017.05.024_bib44","first-page":"4","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","author":"Agarwal","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.jtho.2017.05.024_bib45","doi-asserted-by":"crossref","unstructured":"Cedres S, Ponce Aix S, Zugazagoitia J, et\u00a0al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Abstract presented at: 2014 European Society for Medical Oncology Congress. September 26-30, 2014; Madrid, Spain.","DOI":"10.1093\/annonc\/mdu438.66"},{"key":"10.1016\/j.jtho.2017.05.024_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ijc.21271","article-title":"Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma","volume":"118","author":"Cortese","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2017.05.024_bib47","first-page":"2589","article-title":"Status of anaplastic lymphoma kinase (ALK) in malignant mesothelioma","volume":"34","author":"Varesano","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2017.05.024_bib48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod Path"},{"key":"10.1016\/j.jtho.2017.05.024_bib49","doi-asserted-by":"crossref","first-page":"14470","DOI":"10.1073\/pnas.1212811109","article-title":"An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state","volume":"109","author":"Polytarchou","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2017.05.024_bib50","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1038\/ncomms6203","article-title":"Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER","volume":"5","author":"van den Beucken","year":"2014","journal-title":"Nat Comm"},{"key":"10.1016\/j.jtho.2017.05.024_bib51","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jcmm.12882","article-title":"MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation","volume":"20","author":"Jia","year":"2016","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jtho.2017.05.024_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2017.05.024_bib53","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of malignant pleural mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.024_bib54","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2017.05.024_bib55","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1371\/journal.pbio.0030085","article-title":"Principles of microRNA-target recognition","volume":"3","author":"Brennecke","year":"2005","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jtho.2017.05.024_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2017.05.024_bib57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2012-07-444729","article-title":"Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN\/PI3K signal pathway","volume":"121","author":"Li","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2017.05.024_bib58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","article-title":"Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression","volume":"25","author":"Xu","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2017.05.024_bib59","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur J Cardiothoracic Surg"},{"key":"10.1016\/j.jtho.2017.05.024_bib60","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1164\/rccm.201503-0461LE","article-title":"A\u00a0significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma","volume":"191","author":"Kao","year":"2015","journal-title":"Am J Respir Crit Care Med"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2017.11.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417304604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417304604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T03:10:48Z","timestamp":1569467448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086417304604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1556086417304604"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2017.05.024","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jtho.2017.11.005","asserted-by":"object"}]},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural\u00a0Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}